What is Pliant Therapeutics Inc?
, a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 43.21M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.